Search Results - terry+hinds

4 Results Sort By:
Rapid Nuclear Receptor Fluorescence-Based Competitive Binding Assay
Project ID: 2019-47Background:Peroxisome proliferator-activated receptors (PPARs) are a class of nuclear receptors that have become significant targets for addressing various metabolic disorders, including lipid dystrophies and diabetes. PPARs are nutrient receptors that have different selective and promiscuous ligands, including fatty acids and eicosanoids....
Published: 8/3/2022   |   Inventor(s): Terry Hinds, David Stec, Darren Gordon
Keywords(s): Binding Assay, Fluorescence, LanthaScreen™, Proliferator-Activated Receptors (PPARs), Radioactive Assays
Category(s): Tools
PEGylated Bilirubin for the treatment of Hyperlipidemia, Obesity, and Type II Diabetes
Project ID: D2018-40 Background: Obesity, a low-grade inflammatory disease, has affected more than 150 million people in the US. Obesity and its associated risk factors are a prelude to the development of type II diabetes that accounts for a vast majority of the 25.8 million diabetes cases in the US. Bilirubin, a yellow pigment produced during...
Published: 5/9/2024   |   Inventor(s): Terry Hinds, David Stec
Keywords(s): Bilirubin, Brown Adipose Tissue, Cholesterol, Obesity, PEGylated, PPARα, Triglycerides, Type II Diabetes, White Adipose Tissue
Category(s): Cardiovascular, Renal, & Metabolism
“Thin” Molecules for Treating Obesity and Type II Diabetes
Project ID: D2016-29 IP Status: PCT patent application filed Invention Description and Novelty: “Thin” molecules offer stronger binding to PPAR and include greater lipid burning and glucose lowering properties. Applications: Dyslipidemia, obesity and type II diabetes Value propositions: • Bilirubin reduces body...
Published: 5/9/2024   |   Inventor(s): Terry Hinds, Christopher Trabbic, David Stec
Keywords(s): Adipogenesis, Bilirubin, Biliverdin, Biliverdin Reductase, Fenofibrate, FGF21, Heme Oxygenase, Lipid Accumulation, PPAR, PPARa, WY 14,643
Category(s): Cardiovascular, Renal, & Metabolism
“Sweet-P”: Molecule for Targeting Human Glucocorticoid Receptor Beta in Asthma and Cancer
Project ID: D2016-49Background:Despite many breakthrough innovations occurring in the $14 billion Asthma market, numerous people are still affected by fatal asthma, and the United States contains the largest population affected by severe asthma. Glucocorticoids (GCs) are the most effective and commonly prescribed anti-inflammatory agents in treating...
Published: 5/9/2024   |   Inventor(s): Terry Hinds, Lucien McBeth
Keywords(s): Asthma, Bladder Cancer, Glucocorticoid (GC), Glucocorticoid Receptor α (GRα), Glucocorticoid Receptor β (GRβ), Leukemia, Peptide Nucleic Acid (PNA), Prostate Cancer, Sweet P
Category(s): Oncology, Inflammation & Immunity